Back to Browse Journals » Clinical Audit » Volume 3

Sociodemographic differences in diabetic retinopathy screening; using patient-level primary care data for health equity audit

Authors Fraser SDS, Watkinson GE, Rennie CA, King D, Sanderson H, Edwards L, Roderick P

Published Date November 2011 Volume 2011:3 Pages 7—15

DOI http://dx.doi.org/10.2147/CA.S25313

Published 10 November 2011

Simon DS Fraser1, GE Watkinson2, CA Rennie3, D King2, H Sanderson2, L Edwards4, P Roderick1
1Public Health Sciences and Medical Statistics, University of Southampton, Southampton General Hospital, Southampton, 2NHS Southampton City, Southampton, 3Southampton Eye Unit, Southampton General Hospital, Southampton, 4NHS Hampshire, Eastleigh, Hampshire, UK

Background: The prevalence of diabetes is increasing worldwide and there is inequality in the distribution of diabetic complications. Diabetic retinopathy is the leading cause of blindness in adults of working age in the UK, and certain risk factors are recognized. Retinopathy screening in the UK involves annual digital retinal photography and image grading. Auditing equity in retinopathy screening poses unique challenges, and screening program data are often incomplete for variables relevant to equity. Using two sources of patient-level primary care data, we conducted a health equity audit comparing the access and uptake of screening between groups of people with diabetes in each of three screening programs covering this area of southern England.
Methods: A patient-level dataset using data from general practices and a combined health record was used to compare dimensions of equity (gender, age, length of time since diabetes diagnosis, type of diabetes, presence of hypertension, socioeconomic deprivation, ethnicity, and screening program) between people with and without a record of retinopathy screening within three years in Hampshire and the Isle of Wight, UK.
Results: Anonymized data for 70,004 people with diabetes were obtained from 205 (88%) general practices. In total, 62,836 people (89.8%) had a record of screening within three years and 7168 (10.2%) did not. Lower uptake of screening was independently associated with the youngest and oldest age groups (compared with 50–79-year-olds), recent diabetes diagnosis, and deprived areas. Diagnosed hypertension was positively associated with screening.
Conclusion: Evaluating equity in screening programs is important to help reduce inequalities. We found evidence of inequity in access and uptake of retinopathy screening. Primary care data contained more information than screening program data. Using a combined health record was more efficient than obtaining data directly from general practices, but data were incomplete for deprivation measures at the time of this audit. Our audit informed subsequent efforts to improve equity in local diabetic retinopathy screening services.

Keywords: inequality, diabetes, eye, complications, screening

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes

Nakamura M, Sasai N, Hisatome I, Ichida K

Clinical Pharmacology: Advances and Applications 2014, 6:79-86

Published Date: 3 May 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Arginine-based cationic liposomes for efficient in vitro plasmid DNA delivery with low cytotoxicity

Sarker SR, Aoshima Y, Hokama R, Inoue T, Sou K, Takeoka S

International Journal of Nanomedicine 2013, 8:1361-1375

Published Date: 10 April 2013

Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

Liu L, Ma Y, Wang RL, Xu WR, Wang SQ, Chou KC

Drug Design, Development and Therapy 2013, 7:279-288

Published Date: 8 April 2013

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011